JP2022507020A5 - - Google Patents
Info
- Publication number
- JP2022507020A5 JP2022507020A5 JP2021523948A JP2021523948A JP2022507020A5 JP 2022507020 A5 JP2022507020 A5 JP 2022507020A5 JP 2021523948 A JP2021523948 A JP 2021523948A JP 2021523948 A JP2021523948 A JP 2021523948A JP 2022507020 A5 JP2022507020 A5 JP 2022507020A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- unsubstituted
- pharmaceutically acceptable
- acceptable salt
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862758364P | 2018-11-09 | 2018-11-09 | |
| US62/758,364 | 2018-11-09 | ||
| US201962916739P | 2019-10-17 | 2019-10-17 | |
| US62/916,739 | 2019-10-17 | ||
| PCT/US2019/060350 WO2020097389A1 (en) | 2018-11-09 | 2019-11-07 | Bicyclic compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022507020A JP2022507020A (ja) | 2022-01-18 |
| JP2022507020A5 true JP2022507020A5 (cg-RX-API-DMAC7.html) | 2022-11-07 |
| JP7482861B2 JP7482861B2 (ja) | 2024-05-14 |
Family
ID=70611193
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021523948A Active JP7482861B2 (ja) | 2018-11-09 | 2019-11-07 | 二環式化合物 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US11866431B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3877356A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7482861B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20210108367A (cg-RX-API-DMAC7.html) |
| CN (1) | CN113302175A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019375983A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112021008741A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3118752A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL282984A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2021005314A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020097389A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3877356A4 (en) | 2018-11-09 | 2022-06-22 | Vivace Therapeutics, Inc. | BICYCLIC LINKS |
| WO2020160151A1 (en) * | 2019-01-31 | 2020-08-06 | Kyorin Pharmaceutical Co., Ltd. | 15-pgdh inhibitors |
| AU2020257207B2 (en) | 2019-04-16 | 2026-06-04 | Vivace Therapeutics, Inc. | Bicyclic compounds |
| WO2021224291A1 (en) * | 2020-05-08 | 2021-11-11 | Merck Patent Gmbh | Tricyclic heterocycles useful as tead binders |
| US11787775B2 (en) | 2020-07-24 | 2023-10-17 | Genentech, Inc. | Therapeutic compounds and methods of use |
| AR123656A1 (es) | 2020-09-30 | 2022-12-28 | Univ Leuven Kath | Derivados de 1,2,3,4-tetrahidroquinolina |
| WO2022120355A1 (en) | 2020-12-02 | 2022-06-09 | Ikena Oncology, Inc. | Tead degraders and uses thereof |
| BR112023014751A2 (pt) | 2021-01-25 | 2023-10-03 | Ikena Oncology Inc | Combinação de um inibidor de tead de 3-(imidazol-4-il)-4-(amino)-benzenossulfonamida com um inibidor de egfr e/ou inibidor de mek para uso no tratamento de câncer de pulmão |
| WO2022233442A1 (en) * | 2021-02-10 | 2022-11-10 | Merck Patent Gmbh | 2,8-dihydropyrazolo[3,4-b]indole derivatives for use in the treatment of cancer |
| CN117157278A (zh) * | 2021-03-23 | 2023-12-01 | 柏奥艾奇实验室公司 | Nlrp3炎性体的抑制剂 |
| AU2022241754A1 (en) | 2021-03-23 | 2023-10-19 | BioAge Labs, Inc. | Inhibitors of nlrp3 inflammasome |
| US12655150B2 (en) | 2021-03-26 | 2026-06-16 | Cedilla Therapeutics, Inc. | TEAD inhibitors and uses thereof |
| AU2022258968A1 (en) | 2021-04-16 | 2023-10-19 | Ikena Oncology, Inc. | Mek inhibitors and uses thereof |
| AU2021444255A1 (en) * | 2021-05-05 | 2023-12-21 | Cancer Research Technology Ltd. | 2,8-dihydropyrazolo[3,4-b]indole derivatives for use in the treatment of cancer |
| CN117956996A (zh) * | 2021-05-11 | 2024-04-30 | Opna 生物公司 | 用于yap/tead调节的化合物和方法及其适应证 |
| AR125921A1 (es) * | 2021-05-19 | 2023-08-23 | Genentech Inc | Terapia de combinación |
| WO2022272036A1 (en) * | 2021-06-25 | 2022-12-29 | Cedilla Therapeutics, Inc. | Tead inhibitors and uses thereof |
| EP4385978A4 (en) * | 2021-08-12 | 2025-08-13 | Tyk Medicines Inc | POLYCYCLIC COMPOUND AND ITS USE |
| US20240374571A1 (en) | 2021-09-01 | 2024-11-14 | Novartis Ag | Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers |
| WO2023057371A1 (en) | 2021-10-04 | 2023-04-13 | Basilea Pharmaceutica International Ag, Allschwil | 1,2,4-oxadiazol-5-one derivatives for the treatment of cancer |
| WO2023060227A1 (en) | 2021-10-07 | 2023-04-13 | Ikena Oncology, Inc. | Tead inhibitors and uses thereof |
| CN113861061A (zh) * | 2021-10-25 | 2021-12-31 | 成都市科隆化学品有限公司 | 一种不含无机铵盐的氨基酸酰胺盐酸盐及其合成方法 |
| US12030866B2 (en) | 2021-12-23 | 2024-07-09 | Springworks Therapeutics, Inc. | 2-pyrazole anilines and related analogs for inhibiting YAP/TAZ-TEAD |
| CN114181039A (zh) * | 2021-12-23 | 2022-03-15 | 凯美克(上海)医药科技有限公司 | 一种4,4-二苯基-3-丁烯-1-醇的合成方法 |
| EP4469460A1 (en) | 2022-01-28 | 2024-12-04 | Bioage Labs, Inc. | N-oxide inhibitors of nlrp3 inflammasome |
| WO2023150619A2 (en) | 2022-02-02 | 2023-08-10 | The Katholieke Universiteit Leuven | Tetrahydropyridopyrimidines and related analogs for inhibiting yap/taz-tead |
| AU2023225036A1 (en) * | 2022-02-25 | 2024-07-11 | Katholieke Universiteit Leuven | Dihydroquinazolinones and related analogs for inhibiting yap/taz-tead |
| CN114539080A (zh) * | 2022-03-02 | 2022-05-27 | 八叶草健康产业研究院(厦门)有限公司 | 一种2-(2-氨基-6-氯苯基)-乙酸钠的制备方法 |
| WO2023173053A1 (en) | 2022-03-10 | 2023-09-14 | Ikena Oncology, Inc. | Mek inhibitors and uses thereof |
| WO2023173057A1 (en) | 2022-03-10 | 2023-09-14 | Ikena Oncology, Inc. | Mek inhibitors and uses thereof |
| JP2025513725A (ja) * | 2022-03-22 | 2025-04-30 | スポロス バイオディスカバリー,インク. | Tead阻害剤および使用方法 |
| CN119768393A (zh) | 2022-05-25 | 2025-04-04 | 医肯纳肿瘤学公司 | Mek抑制剂和其用途 |
| TW202409001A (zh) | 2022-07-06 | 2024-03-01 | 美商維維迪昂醫療公司 | 包含wrn解旋酶抑制劑之醫藥組成物 |
| CN119968359A (zh) | 2022-09-29 | 2025-05-09 | 英矽智能科技知识产权有限公司 | Tead抑制剂及其使用方法 |
| WO2024092116A1 (en) | 2022-10-26 | 2024-05-02 | Ikena Oncology, Inc. | Combination of tead inhibitors and egfr inhibitors and uses thereof |
| WO2024105610A1 (en) | 2022-11-18 | 2024-05-23 | Novartis Ag | Pharmaceutical combinations and uses thereof |
| WO2024173761A1 (en) | 2023-02-17 | 2024-08-22 | Ikena Oncology, Inc. | Combinations comprising mek inhibitors for use in the treatment of cancer |
| CN120659608A (zh) | 2023-02-23 | 2025-09-16 | 诺华股份有限公司 | 用于治疗癌症的tead抑制剂和kras g12d抑制剂组合 |
| EP4669319A1 (en) | 2023-02-23 | 2025-12-31 | Novartis AG | TEAD AND HER2 INHIBITOR COMBINATIONS FOR CANCER TREATMENT |
| JP2026519523A (ja) * | 2023-05-24 | 2026-06-16 | ビアクティカ セラピューティクス エービー | Teadへの結合剤としての芳香族アミドおよびそのコンジュゲート |
| WO2025054190A1 (en) * | 2023-09-05 | 2025-03-13 | Vivace Therapeutics, Inc. | Pharmaceutical formulations and dosing schedules of a yap/taz-tead inhibitor |
| CN117327007B (zh) * | 2023-09-26 | 2024-09-13 | 上海陶术生物科技有限公司 | 一种vt107的制备方法 |
| WO2025101655A1 (en) * | 2023-11-08 | 2025-05-15 | Vivace Therapeutics, Inc. | Compounds for modulating yap-tead/hippo pathway |
| WO2025141118A1 (en) | 2023-12-27 | 2025-07-03 | Institut National de la Santé et de la Recherche Médicale | Arylalkyloxyindole compounds and derivatives and their use |
| WO2025207644A1 (en) | 2024-03-26 | 2025-10-02 | BioAge Labs, Inc. | Inhibitors of nlrp3 inflammasome |
| TW202547484A (zh) | 2024-04-10 | 2025-12-16 | 瑞士商諾華公司 | 藥物組合及其用途 |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL135495A (en) | 1995-09-28 | 2002-12-01 | Hoechst Ag | Intermediate compounds for the preparation of quinoline-converted amines - 2 - carboxylic acid |
| JP2001511813A (ja) * | 1997-02-18 | 2001-08-14 | ニューロクライン バイオサイエンシーズ,インコーポレイテッド | Crfレセプターアンタゴニストおよびそれらに関連する方法 |
| EP1042295B1 (en) | 1997-12-22 | 2005-09-07 | Pharmacia & Upjohn Company LLC | 4-hydroxyquinoline-3-carboxamides and hydrazides as antiviral agents |
| IT1303123B1 (it) | 1998-10-13 | 2000-10-30 | Rotta Research Lab | Derivati basici di benz(e)isoindol-1-oni e pirrolo(3,4-c)chinolin-1-oni ad attivita' 5ht3 antagonista, loro preparazione ed |
| HK1045306A1 (zh) | 1999-06-03 | 2002-11-22 | Abbott Laboratories | 抑制细胞黏附的抗炎化合物 |
| AUPQ841300A0 (en) | 2000-06-27 | 2000-07-20 | Fujisawa Pharmaceutical Co., Ltd. | New aminoalcohol derivatives |
| US7067532B2 (en) | 2000-11-02 | 2006-06-27 | Astrazeneca | Substituted quinolines as antitumor agents |
| FR2827599A1 (fr) * | 2001-07-20 | 2003-01-24 | Neuro3D | Composes derives de quinoleine et quinoxaline,preparation et utilisations |
| US7544699B2 (en) | 2003-08-08 | 2009-06-09 | Transtech Pharma, Inc. | Aryl and heteroaryl compounds, compositions, and methods of use |
| WO2005082865A1 (ja) | 2004-02-27 | 2005-09-09 | Astellas Pharma Inc. | 縮合二環性ピリミジン誘導体 |
| JP4847459B2 (ja) | 2005-01-25 | 2011-12-28 | 田辺三菱製薬株式会社 | ノルバリン誘導体及びその製造方法 |
| CN102351791B (zh) | 2006-01-27 | 2014-10-29 | 菲布罗根有限公司 | 使低氧诱导因子(hif)稳定的氰基异喹啉化合物 |
| US20070259960A1 (en) | 2006-02-16 | 2007-11-08 | Fibrogen, Inc. | Compounds and methods for treatment of stroke |
| UY30183A1 (es) | 2006-03-02 | 2007-10-31 | Astrazeneca Ab | Derivados de quinolina |
| WO2008023157A1 (en) | 2006-08-21 | 2008-02-28 | Argenta Discovery Limited | Nitrogen containing heterocyclic compounds useful as m3-receptor modulators |
| AR065093A1 (es) * | 2007-02-05 | 2009-05-13 | Merck Frosst Canada Ltd | Compuestos farmacéuticos inhibidores de la biosintesis de leucotrienos |
| EP2481735A1 (en) | 2007-05-09 | 2012-08-01 | Pfizer Inc. | Substituted heterocyclic derivatives and compositions and their pharmaceutical use as antibacterials |
| ES2614269T3 (es) * | 2007-08-03 | 2017-05-30 | Biotron Limited | Procedimientos y composiciones antivíricas frente a la hepatitis C |
| BRPI0819453A2 (pt) | 2007-11-28 | 2014-10-07 | Dana Farber Cancer Inst Inc | Composto, métodos para tratar um distúrbio relacionado com atividade de cinase, para tratar câncer em um paciente, para inibir a atividade de cinase e para identificar um composto que modula a atividade de cinase de bcr-abl, composição farmacêutica, e, kit |
| EP2231156A1 (en) | 2007-12-07 | 2010-09-29 | Fibrogen, Inc. | Methods for increasing white blood cells |
| BRPI1013988A2 (pt) * | 2009-04-06 | 2016-04-05 | Daiichi Sankyo Co Ltd | composto, composição farmacêutica , e, uso de um composto ou um sal farmacologicamente aceitável do mesmo |
| AU2010239188B2 (en) | 2009-04-22 | 2016-03-31 | Janssen Pharmaceutica Nv | Azetidinyl diamides as monoacylglycerol lipase inhibitors |
| EP2588455B1 (en) * | 2010-07-02 | 2018-04-04 | Gilead Sciences, Inc. | 2-quinolinyl-acetic acid derivatives as hiv antiviral compounds |
| KR20130140020A (ko) * | 2010-10-22 | 2013-12-23 | 얀센 파마슈티카 엔.브이. | 모노아실글리세롤 리파아제 억제제로서의 아미노-피롤리딘-아제티딘 다이아미드 |
| CA2743391A1 (en) | 2011-05-27 | 2012-11-27 | Queen's University At Kingston | Compounds and methods for catalytic directed ortho substitution of aromatic amides and esters |
| US9278960B2 (en) | 2011-11-03 | 2016-03-08 | Merck Sharp & Dohme Corp. | Quinoline carboxamide and quinoline carbonitrile derivatives as mGluR2-negative allosteric modulators, compositions, and their use |
| WO2013086229A1 (en) | 2011-12-07 | 2013-06-13 | Amgen Inc. | Bicyclic aryl and heteroaryl sodium channel inhibitors |
| US20150157584A1 (en) | 2012-06-11 | 2015-06-11 | The J. David Gladstone Institutes | Inhibitors of hippo-yap signaling pathway |
| SG11201500234YA (en) | 2012-07-16 | 2015-02-27 | Fibrogen Inc | Process for making isoquinoline compounds |
| JP6113354B2 (ja) * | 2013-05-03 | 2017-04-12 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 神経新生刺激イソキノリン誘導体 |
| US20140336182A1 (en) | 2013-05-13 | 2014-11-13 | Amgen Inc. | Aurora Kinase Modulators and Method of Use |
| US9212182B2 (en) | 2013-06-12 | 2015-12-15 | Amgen Inc. | Bicyclic sulfonamide compounds as sodium channel inhibitors |
| MX2016010056A (es) | 2014-02-06 | 2016-11-15 | Abbvie Inc | 6-heteroariloxi o 6-ariloxi-quinolina-2-carboxamidas y metodos de uso. |
| JP6377245B2 (ja) | 2014-03-24 | 2018-08-22 | グアンドン ジョンシェン ファーマシューティカル カンパニー リミテッド | Smo阻害剤としてのキノリン誘導体 |
| EP3247705B1 (en) | 2015-01-20 | 2019-11-20 | Millennium Pharmaceuticals, Inc. | Quinazoline and quinoline compounds and uses thereof as nampt inhibitors |
| EP3156404A1 (en) | 2015-10-15 | 2017-04-19 | Inventiva | New compounds inhibitors of the yap/taz-tead interaction and their use in the treatment of malignant mesothelioma |
| EP3868750A1 (en) | 2015-11-20 | 2021-08-25 | Vitae Pharmaceuticals, LLC | Modulators of ror-gamma |
| WO2018028591A1 (zh) | 2016-08-09 | 2018-02-15 | 殷建明 | 一种喹啉衍生物及其用途 |
| WO2019040389A1 (en) | 2017-08-21 | 2019-02-28 | Palmese Giuseppe R | RENEWABLE FURANE AMINE CURING AGENTS FOR THERMOSETTING EPOXY PLASTIC |
| HRP20251184T1 (hr) | 2018-01-26 | 2025-12-05 | Exelixis, Inc. | Spojevi za liječenje poremećaja ovisnih o kinazi |
| CN112236172A (zh) * | 2018-01-30 | 2021-01-15 | 福宏治疗公司 | 用于治疗病症的方法和化合物 |
| EP3877356A4 (en) | 2018-11-09 | 2022-06-22 | Vivace Therapeutics, Inc. | BICYCLIC LINKS |
| AU2020257207B2 (en) | 2019-04-16 | 2026-06-04 | Vivace Therapeutics, Inc. | Bicyclic compounds |
| US20240025913A1 (en) | 2020-10-21 | 2024-01-25 | Vivace Therapeutics, Inc. | Tertiary carboxamide compounds |
-
2019
- 2019-11-07 EP EP19882564.8A patent/EP3877356A4/en not_active Withdrawn
- 2019-11-07 WO PCT/US2019/060350 patent/WO2020097389A1/en not_active Ceased
- 2019-11-07 BR BR112021008741-9A patent/BR112021008741A2/pt not_active Application Discontinuation
- 2019-11-07 AU AU2019375983A patent/AU2019375983A1/en not_active Abandoned
- 2019-11-07 US US17/291,765 patent/US11866431B2/en active Active
- 2019-11-07 CN CN201980088541.5A patent/CN113302175A/zh active Pending
- 2019-11-07 JP JP2021523948A patent/JP7482861B2/ja active Active
- 2019-11-07 CA CA3118752A patent/CA3118752A1/en active Pending
- 2019-11-07 KR KR1020217017366A patent/KR20210108367A/ko not_active Ceased
- 2019-11-07 MX MX2021005314A patent/MX2021005314A/es unknown
-
2021
- 2021-05-06 IL IL282984A patent/IL282984A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7653362B2 (ja) | 二環式化合物 | |
| JP2020533280A5 (cg-RX-API-DMAC7.html) | ||
| ES2791315T3 (es) | Agonistas triazoles del receptor APJ | |
| JP2018515581A5 (cg-RX-API-DMAC7.html) | ||
| JP2020518669A5 (cg-RX-API-DMAC7.html) | ||
| RU2491286C1 (ru) | Полиморфная форма соединения 2-аминотиазола в качестве ингибитора киназы и способ ее получения | |
| JP2022529700A5 (cg-RX-API-DMAC7.html) | ||
| JP2022529642A5 (cg-RX-API-DMAC7.html) | ||
| JP2021519783A5 (cg-RX-API-DMAC7.html) | ||
| ES2911040T3 (es) | Nuevos derivados de heteroaril amida como inhibidores selectivos de histona deacetilasa 1 y 2 (HDAC1/2) | |
| ES2908938T3 (es) | Nuevos derivados de benzamida como moduladores de PPAR-gamma | |
| US7951957B2 (en) | Substituted benzimidazoles and their use for inducing apoptosis | |
| JP2019514883A5 (cg-RX-API-DMAC7.html) | ||
| CA2885969A1 (en) | Substitued pyridine derivatives and compositions thereof useful as inhibitors of histone demethylases | |
| AU2004268621A1 (en) | c-Kit modulators and methods of use | |
| PT1089998E (pt) | Derivados de epotilona e sua síntese e utilização | |
| EA026892B1 (ru) | ТРИАЗОЛОНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ mPGES-1 | |
| JP2008520742A5 (cg-RX-API-DMAC7.html) | ||
| JP2005505595A5 (cg-RX-API-DMAC7.html) | ||
| JP2021523168A5 (cg-RX-API-DMAC7.html) | ||
| ES2300775T3 (es) | Furazanobencimidazoles. | |
| ES2338060T3 (es) | Componentes de tipo ariloxi y ariltoxia-cetofenona para el tratamiento del cancer. | |
| EP3303290A1 (en) | Ror gamma (rory) modulators | |
| JP2018515491A5 (cg-RX-API-DMAC7.html) | ||
| AU2015218775C1 (en) | Antimitotic amides for the treatment of cancer and proliferative disorders |